{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T16:18:41Z","timestamp":1788020321425,"version":"build-2784847793"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,29]]},"DOI":"10.7759\/cureus.115402","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T15:50:00Z","timestamp":1788018600000},"source":"Crossref","is-referenced-by-count":0,"title":["Givosiran for the Treatment of Hereditary Coproporphyria in Pregnancy: A Case Report"],"prefix":"10.7759","author":[{"given":"Tess","family":"Van Schoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shea A","family":"Nagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall Y","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29313","article-title":"Acute hepatic porphyrias: recommendations for evaluation and long-term management","volume":"66","author":"Balwani M","year":"2017","unstructured":"Balwani M, Wang B, Anderson KE, et al.. Acute hepatic porphyrias: recommendations for evaluation and long-term management. Hepatology. 2017, 66:1314-22. 10.1002\/hep.29313","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1007137","article-title":"Hereditary coproporphyria","volume":"18","author":"Mart\u00e1sek P","year":"1998","unstructured":"Mart\u00e1sek P. Hereditary coproporphyria. Semin Liver Dis. 1998, 18:25-32. 10.1055\/s-2007-1007137","journal-title":"Semin Liver Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70156","article-title":"A prospective, blinded study of symptom prevalence and specificity of porphyrin precursors in carriers of acute hepatic porphyria","volume":"45","author":"Merati M","year":"2025","unstructured":"Merati M, Jayakumar N, Kapoor Y, et al.. A prospective, blinded study of symptom prevalence and specificity of porphyrin precursors in carriers of acute hepatic porphyria. Liver Int. 2025, 45:e70156. 10.1111\/liv.70156","journal-title":"Liver Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.11.034","article-title":"AGA clinical practice update on diagnosis and management of acute hepatic porphyrias: expert review","volume":"164","author":"Wang B","year":"2023","unstructured":"Wang B, Bonkovsky HL, Lim JK, Balwani M. AGA clinical practice update on diagnosis and management of acute hepatic porphyrias: expert review. Gastroenterology. 2023, 164:484-91. 10.1053\/j.gastro.2022.11.034","journal-title":"Gastroenterology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2022.2075848","article-title":"Givosiran for the treatment of acute hepatic porphyria","volume":"15","author":"Ricci A","year":"2022","unstructured":"Ricci A, Ventura P. Givosiran for the treatment of acute hepatic porphyria. Expert Rev Clin Pharmacol. 2022, 15:383-93. 10.1080\/17512433.2022.2075848","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref6","unstructured":"Alnylam Pharmaceuticals. Givosiran. Package insert. (2019). Accessed. June 3, 2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/0212194s000lbl.pdf."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S281631","article-title":"Spotlight on givosiran as a treatment option for adults with acute hepatic porphyria: design, development, and place in therapy","volume":"16","author":"Majeed CN","year":"2022","unstructured":"Majeed CN, Ma CD, Xiao T, Rudnick S, Bonkovsky HL. Spotlight on givosiran as a treatment option for adults with acute hepatic porphyria: design, development, and place in therapy. Drug Des Devel Ther. 2022, 16:1827-45. 10.2147\/DDDT.S281631","journal-title":"Drug Des Devel Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nm1005-1049","article-title":"Fast track to the porphyrias","volume":"11","author":"Phillips JD","year":"2005","unstructured":"Phillips JD, Kushner JP. Fast track to the porphyrias. Nat Med. 2005, 11:1049-50. 10.1038\/nm1005-1049","journal-title":"Nat Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.06.040","article-title":"Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha","volume":"122","author":"Handschin C","year":"2005","unstructured":"Handschin C, Lin J, Rhee J, et al.. Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. Cell. 2005, 122:505-15. 10.1016\/j.cell.2005.06.040","journal-title":"Cell"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3109\/00016340903390729","article-title":"Evaluation of gonadotropin-releasing hormone agonist treatment for prevention of menstrual-related attacks in acute porphyria","volume":"89","author":"Innala E","year":"2010","unstructured":"Innala E, B\u00e4ckstr\u00f6m T, Bixo M, Andersson C. Evaluation of gonadotropin-releasing hormone agonist treatment for prevention of menstrual-related attacks in acute porphyria. Acta Obstet Gynecol Scand. 2010, 89:95-100. 10.3109\/00016340903390729","journal-title":"Acta Obstet Gynecol Scand"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000664960.20982.31","article-title":"Pregnancy outcomes in women with acute porphyria: a systematic literature review [35G]","volume":"135","author":"Kanninen TT","year":"2020","unstructured":"Kanninen TT, Stroobant E, Pierce-Williams R, Berger S, Al-Kouatly HB. Pregnancy outcomes in women with acute porphyria: a systematic literature review [35G]. Obstet Gynecol. 2020, 135:80. 10.1097\/01.AOG.0000664960.20982.31","journal-title":"Obstet Gynecol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-010-9231-2","article-title":"Excess risk of adverse pregnancy outcomes in women with porphyria: a population-based cohort study","volume":"34","author":"Toll\u00e5nes MC","year":"2011","unstructured":"Toll\u00e5nes MC, Aarsand AK, Sandberg S. Excess risk of adverse pregnancy outcomes in women with porphyria: a population-based cohort study. J Inherit Metab Dis. 2011, 34:217-23. 10.1007\/s10545-010-9231-2","journal-title":"J Inherit Metab Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12616","article-title":"Maternal and fetal outcomes in acute hepatic porphyria: a Swedish National Cohort Study","volume":"46","author":"Mantel \u00c4","year":"2023","unstructured":"Mantel \u00c4, Vassiliou D, Lissing M, Stephansson O, Wahlin S, Sardh E. Maternal and fetal outcomes in acute hepatic porphyria: a Swedish National Cohort Study. J Inherit Metab Dis. 2023, 46:675-86. 10.1002\/jimd.12616","journal-title":"J Inherit Metab Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria","volume":"382","author":"Balwani M","year":"2020","unstructured":"Balwani M, Sardh E, Ventura P, et al.. Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria. N Engl J Med. 2020, 382:2289-301. 10.1056\/NEJMoa1913147","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.013","article-title":"Efficacy and safety of givosiran for acute hepatic porphyria: final results of the randomized phase III ENVISION trial","volume":"79","author":"Kuter DJ","year":"2023","unstructured":"Kuter DJ, Bonkovsky HL, Monroy S, et al.. Efficacy and safety of givosiran for acute hepatic porphyria: final results of the randomized phase III ENVISION trial. J Hepatol. 2023, 79:1150-8. 10.1016\/j.jhep.2023.06.013","journal-title":"J Hepatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/514533-givosiran-for-the-treatment-of-hereditary-coproporphyria-in-pregnancy-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T15:50:01Z","timestamp":1788018601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/514533-givosiran-for-the-treatment-of-hereditary-coproporphyria-in-pregnancy-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.115402","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,29]]}}}